

Afirma.

GENOMIC SEQUENCING CLASSIFIER

Development and Validation of Classifiers to Enhance the Afirma Genomic Sequencing Classifier Performance Among Hürthle Cell Specimens

Presented at the
**87th Annual Meeting of the
American Thyroid Association**

October 18-22
Victoria, BC, Canada



6000 Shoreline Court, Suite 300
South San Francisco, CA 94080
www.veracyte.com
1.888.9AFIRMA (888.923.4762)

Development and Validation of Classifiers to Enhance the Afirma Genomic Sequencing Classifier Performance Among Hürthle Cell Specimens

Duh, Quan-Yang¹; Angell, Trevor E.²; Babiarz, Joshua³; Barth, Neil³; Blevins, Thomas⁴; Ghossein, Ronald A.⁵; Harrell, R. M.⁶; Huang, Jing³; Kim, Su Yeon³; Kloos, Richard T.³; Ladenson, Paul W.⁷; LiVolsi, Virginia A.⁸; Patel, Kpal N.⁹; Randolph, Gregory¹⁰; Sadow, Peter M.¹¹; Shanik, Michael H.¹²; Sosa, Julie Ann¹³; Traweek, S. T.¹⁴; Walsh, P. S.³; Yeh, Michael¹⁵; Kennedy, Giulia³

1. Department of Surgery, Section of Endocrine Surgery, University of California San Francisco, San Francisco, CA. 2. Department of Medicine, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. 3. Veracyte, Inc., South San Francisco, CA. 4. Texas Diabetes and Endocrinology, Austin, TX. 5. Department of Pathology, Division of Head and Neck Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY. 6. The Memorial Center for Integrative Endocrine Surgery, Boca Raton, FL. 7. Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University, Baltimore, MD. 8. Department of Pathology and Laboratory Medicine, Anatomic Pathology Division, University of Pennsylvania School of Medicine, Philadelphia, PA. 9. Department of Surgery, Division of Endocrine Surgery, NYU Langone Medical Center, New York, NY. 10. Department of Otolaryngology, Division of Thyroid and Parathyroid Endocrine Surgery, Massachusetts Eye and Ear and Harvard Medical School, Boston, MA. 11. Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA. 12. Endocrine Associates of Long Island, Smithtown, NY. 13. Department of Surgery and Duke Cancer Institute, Duke University Medical Center, Durham, NC. 14. Thyroid Cytopathology Partners, Austin, TX. 15. Department of Surgery, Endocrine Surgery Program, UCLA David Geffen School of Medicine, Los Angeles, CA.

INTRODUCTION


Most Hürthle cell dominant Bethesda III+IV thyroid nodules undergo diagnostic surgery, yet most are histologically benign. The Gene Expression Classifier (GEC) provided these samples a high NPV, but most were GEC suspicious. To maintain a high NPV while providing more benign results, we built two dedicated classifiers to work with the core Genomic Sequencing Classifier (GSC), which uses RNA sequencing and machine learning algorithms to identify benign nodules preoperatively with overall 91.1% sensitivity and an improved 68.3% specificity.

METHODS

A Hürthle cell classifier was developed using 1,408 nuclear and mitochondrial genes to differentiate Hürthle cytology specimens (H+) from non-Hürthle specimens (H-). A separate Hürthle neoplasm classifier was developed using 2,041 genes and a chromosome-level loss-of-heterozygosity statistic built from 189,731 genomic variants to differentiate Hürthle neoplastic specimens (N+) from non-neoplastic Hürthle specimens (N-), only among H+ specimens (Figure 1). H+N+ and all H- specimens are subject to the canonical GSC

cutoff, while an adjusted threshold is used only for H+N- specimens. The adjusted threshold is applied due to the fact that non-neoplastic nodules are less likely to be malignant. We applied this process in a blinded fashion to the prospective, multicenter, and blinded Bethesda III+IV samples that originally validated the GEC, of which 191 had sufficient remaining RNA.¹

FIGURE 1:
Four Hürthle Categories Designed to Reduce False Positives



REFERENCES
1. Alexander, EK et al. *NEJM* 2012

RESULTS

1 MTC, 3 BRAF V600E+ PTC, and 1 with inadequate follicular cell content were identified by upstream classifiers, leaving 186 specimens for GSC core classifier testing, of which 37 (20%) resulted H+; among these, 16 were classified as Hürthle non-neoplastic (N-). Among these H+N- specimens, 9 (56%) had canonical benign GSC scores and would result GSC benign by either threshold. However, the Hürthle-adjusted threshold rescued the other 44% to a benign result (Figure 2). Among the 26 Hürthle cell adenomas and carcinomas, the final GSC sensitivity for malignancy identification was 88.9%, and the specificity to identify benign lesions was 58.8%, a 47% absolute improvement of specificity above the previous GEC (Table 1).

FIGURE 2:
Adjusted Threshold Increases Specificity




TABLE 1.
Afirma GSC has Significantly Improved Specificity in Hürthle and Non-Hürthle Specimens

	Hürthle (n=26)			Non-Hürthle (n=164)		
Afirma GEC	Sensitivity 88.9% [51.8-99.7]	Specificity 11.8% [1.46-36.4]	B-Call 11.5%	Sensitivity 88.9% [73.9-96.9]	Specificity 55.5% [46.4-64.3]	B-Call 45.7%
Afirma GSC	Sensitivity 88.9% [51.8-99.7]	Specificity 58.8% [32.9-81.6]	B-Call 42.3%	Sensitivity 91.7% [77.5-98.2]	Specificity 69.5% [60.8-77.4]	B-Call 56.1%
	GAIN 47% Specificity improvement by GSC is substantial on Hürthle (p = 0.012)			GAIN 14% (p=0.028)		

CONCLUSION

The improved overall GSC specificity results from improvements among both Hürthle and non-Hürthle Bethesda III+IV specimens. GSC testing of both Hürthle and non-Hürthle nodules may safely reduce unnecessary diagnostic surgery.